Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Funafuti Tech Report.
Press releases published on September 4, 2025
Cidara Therapeutics to Participate in September Investor Conferences
GlobeNewswire
·
September 4, 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will …
Procedureflow Appoints Sarah Jeanneault as Vice President of Marketing
GlobeNewswire
·
September 4, 2025
SAINT JOHN, New Brunswick, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Procedureflow, a leading provider of knowledge management software, today announced the appointment of Sarah Jeanneault as Vice President of Marketing. Sarah brings more than 20 years of …
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being …
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
GlobeNewswire
·
September 4, 2025
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply …
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
GlobeNewswire
·
September 4, 2025
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of Pinnacle 21 Enterprise Plus. The solution enables clinical and statistical programmers to efficiently create …
Cerence AI and SiMa.ai Partner to Power Next-Gen Conversational AI at the Edge
GlobeNewswire
·
September 4, 2025
AI industry leaders join forces to unlock intelligent, low-power voice interaction for automotive applications SUMMARY AND KEY POINTS: Cerence AI and SiMa.ai partner to run CaLLM Edge on SiMa’s Modalix MLSoC, bringing advanced, low-power conversational AI …
Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025
GlobeNewswire
·
September 4, 2025
Data showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by SKYLINE participants through month 36 and DAWN participants at 9 months or …
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
GlobeNewswire
·
September 4, 2025
WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the Symposium on Advanced Wound …
Cority Adds Revenue Leader Emily Crawford to Meet Rising Demand for EHS+ Consolidation
GlobeNewswire
·
September 4, 2025
TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cority, the sustainable performance software company, today announced the appointment of Emily Crawford as chief revenue officer (CRO). Crawford will oversee global sales, partnerships, and solutions during a …
Byrna Technologies Announces Preliminary Fiscal Record Third Quarter Revenues of $28.2 Million, Up 35% From Fiscal Q3 2024
GlobeNewswire
·
September 4, 2025
ANDOVER, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security …
ORYZON Finalist at the 2025 European Lifestars Awards
GlobeNewswire
·
September 4, 2025
MADRID, Spain and CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has been selected …
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire
·
September 4, 2025
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic …
Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D
GlobeNewswire
·
September 4, 2025
AZURE-2 evaluates the efficacy and safety of brelovitug as a monotherapy compared head-to-head with Hepcludex (bulevirtide) Enrollment in AZURE-1, a global pivotal clinical trial evaluating the efficacy and safety of brelovitug compared to delayed …
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
·
September 4, 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today …
Rocket Doctor Is Now In-Network for Aetna in New York State for Medicare and Commercial Health Insurance
GlobeNewswire
·
September 4, 2025
Rocket Doctor is now in-network with Aetna, having been fully credentialed for Medicare and Commercial insurance in New York State. Aetna is one of the nation’s largest health insurers, covering 39 million members across 16 states. Aetna …
Valitor Presents New Preclinical Data Demonstrating VLTR-559, an Anti-VEGF Drug Candidate for Wet AMD with a Twice-Yearly “Treat-and-Release” Regimen, Exhibits Favorable Safety Profile Similar to Short-Acting Anti-VEGFs
GlobeNewswire
·
September 4, 2025
Tolerability of VLTR-559 assessed at the anticipated clinical dose for less frequent dosing Positive safety results observed across multiple measures of eye health, including intraocular pressure and ophthalmic examination scores Data featured in a …
Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
GlobeNewswire
·
September 4, 2025
Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action that normalizes VEGF expression. End of study, 40-week …
Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression
GlobeNewswire
·
September 4, 2025
Regen’s Approach Could Be Paradigm Shift in Supportive Oncology Care SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) today announced its ongoing efforts to expand the clinical development of HemaXellerate, its novel …
AgEagle Aerial Systems MicaSense Series RedEdge-P Multispectral Camera Available Now on Ascent’s SPIRIT™ and SPARTAN™ UAV Platforms
GlobeNewswire
·
September 4, 2025
Collaboration Delivers Best-In-Class Multispectral Sensor with Rugged, All-Weather VTOL Hardware to Advance UAS Capabilities in Agricultural and Research Applications WICHITA, Kan., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS …
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
GlobeNewswire
·
September 4, 2025
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study with no …